<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="mena-mig01/PMC5629135/results/search/mena-migration/results.xml">
  <result pre="Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and" exact="North Africa" post="Region DagenaisRenée1WilbyKyle John+974 4403 5606kjw@qu.edu.qa2ElewaHazem2EnsomMary H. H.13[1], 0000 0001"/>
  <result pre="outcomes with phenytoin yet effects in the Middle East and" exact="North Africa" post="region are poorly understood. Objectives The objective of this"/>
  <result pre="clinical outcomes in populations originating from the Middle East and" exact="North Africa" post="region, and to characterize genotypic and allelic frequencies within"/>
  <result pre="pharmacokinetics were performed in patients of the Middle East and" exact="North Africa" post="region. Study quality was assessed using a National Institutes"/>
  <result pre="frequencies of assessed genetic polymorphisms within the Middle East and" exact="North Africa" post="region. Results Five studies met the inclusion criteria. CYP2C9,"/>
  <result pre="both between and within countries of the Middle East and" exact="North Africa" post="region. Conclusions CYP2C9 decrease-of-function alleles altered phenytoin pharmacokinetics in"/>
  <result pre="phenytoin pharmacokinetics in patients originating from the Middle East and" exact="North Africa" post="region. The impacts of CYP2C19 and multidrug resistance protein"/>
  <result pre="Key Points In patients originating from the Middle East and" exact="North Africa" post="region, phenytoin metabolism was significantly decreased by genetic polymorphisms"/>
  <result pre="been conducted in patients originating from the Middle East and" exact="North Africa" post="(MENA) region [11, 12]. As a result of migration"/>
  <result pre="North Africa (MENA) region [11, 12]. As a result of" exact="migration" post="and significant admixture of European, Asian, and African populations"/>
  <result pre="and African populations dating back over thousands of years, the" exact="MENA" post="region has a unique genetic diversity, with great variability"/>
  <result pre="allelic frequencies (MAF) of genetic polymorphisms [13–15]. Even within the" exact="MENA" post="region itself, there is great diversity. For example, while"/>
  <result pre="Furthermore, as a result of consanguinity, some countries within the" exact="MENA" post="region may exhibit relatively less genetic diversity [15]. Therefore,"/>
  <result pre="the associated implications regarding phenytoin in individuals originating from the" exact="MENA" post="region is warranted. The primary objective of this systematic"/>
  <result pre="polymorphisms on phenytoin pharmacokinetics, specifically in populations originating from the" exact="MENA" post="region. Secondary objectives were to evaluate the impact of"/>
  <result pre="of each polymorphism identified in the primary search within the" exact="MENA" post="region. Methods Search Strategy A comprehensive search of the"/>
  <result pre="conducted to identify the reported variant MAF, specifically within the" exact="MENA" post="region. Selection of Studies Studies were eligible for inclusion"/>
  <result pre="Studies were eligible for inclusion if participants originated from the" exact="MENA" post="region, received at least one dose of phenytoin with"/>
  <result pre="variant MAF, studies were included if participants originated from the" exact="MENA" post="region and were genotyped for one or more of"/>
  <result pre="results. For studies also including participants from outside of the" exact="MENA" post="region, only data regarding participants who originated from the"/>
  <result pre="MENA region, only data regarding participants who originated from the" exact="MENA" post="region were extracted. Similarly, for studies included in the"/>
  <result pre="inclusion also reported data from participants originating outside of the" exact="MENA" post="region, only data on participants who originated from the"/>
  <result pre="MENA region, only data on participants who originated from the" exact="MENA" post="region were extracted. Quality Assessment The quality of each"/>
  <result pre="polymorphism were assessed to estimate variants’ MAF range within the" exact="MENA" post="region. Results Study Selection A total of five studies"/>
  <result pre="eligibility, ten were excluded for subjects not originating from the" exact="MENA" post="region [17–26], seven were excluded for phenytoin concentrations not"/>
  <result pre="five were excluded for both subjects not originating from the" exact="MENA" post="region and phenytoin concentrations not being assessed [34–38], one"/>
  <result pre="reviews and meta-analyses (PRISMA) flow chart of included studies [146]." exact="MENA" post="Middle East and North Africa, PHT phenytoin Table 1"/>
  <result pre="flow chart of included studies [146]. MENA Middle East and" exact="North Africa," post="PHT phenytoin Table 1 Summary of studies assessing the"/>
  <result pre="interest A total of 82 studies were conducted within the" exact="MENA" post="region and investigated the prevalence of CYP2C9, CYP2C19, and/or"/>
  <result pre="and allelic frequencies of CYP2C9 in the Middle East and" exact="North Africa" post="region References Country Study population Sample size Genotypic frequencies"/>
  <result pre="and allelic frequencies of CYP2C19 in the Middle East and" exact="North Africa" post="region References Country Study population Sample size Genotypic frequencies"/>
  <result pre="frequencies of MDR1 (ABCB1) C3435T in the Middle East and" exact="North Africa" post="region References Country Study population Sample size Genotypic frequencies"/>
  <result pre="volunteers 130 25.4 44.6 30.0 47.7 52.3 Patients with familial" exact="Mediterranean" post="fever 142 16.9 59.9 23.2 46.8 53.2 [115] Turkey"/>
  <result pre="volunteers 250 27.2 42.4 30.4 48.4 51.6 Patients with familial" exact="Mediterranean" post="fever 309 20.4 55.3 24.3 48.1 51.9 [116] Turkey"/>
  <result pre="20.4 55.3 24.3 48.1 51.9 [116] Turkey Patients with familial" exact="Mediterranean" post="fever 41 3.7 54.2 43.4 29.2 70.8 [117] Turkey"/>
  <result pre="respectively (p &amp;lt; 0.0001). Genotypic and Allelic Frequencies Within the" exact="MENA" post="Region Variant MAF of CYP2C9, CYP2C19, and MDR1 (ABCB1)"/>
  <result pre="in a variety of settings and study populations across the" exact="MENA" post="region. Studies from 11 different countries were identified for"/>
  <result pre="variability in MAF both between and within countries of the" exact="MENA" post="region for each of CYP2C9, CYP2C19, and MDR1 (ABCB1)"/>
  <result pre="pharmacokinetics and clinical outcomes specifically in populations originating from the" exact="MENA" post="region, and to characterize assessed polymorphism variant MAF within"/>
  <result pre="conducted in Asian, Caucasian (under which populations originating from the" exact="MENA" post="region were classified), and Indian populations investigated the role"/>
  <result pre="linkage disequilibrium block [138]. Genotypic and Allelic Frequencies Within the" exact="MENA" post="Region Variability in genotypic and allelic frequencies of CYP2C9,"/>
  <result pre="CYP2C9, CYP2C19, and MDR1 C3435T both between and within the" exact="MENA" post="countries for which data were identified was not unexpected."/>
  <result pre="not available for comparison, nor were comparative data specific to" exact="North Africa" post="populations. Ethnicity significantly affects distributions of variants [124] and"/>
  <result pre="to differences in MAF reported for populations outside of the" exact="MENA" post="region for each of CYP2C9 [48, 50, 53, 57,"/>
  <result pre="in the primary analysis, only three different countries within the" exact="MENA" post="region were represented by study populations, with three of"/>
  <result pre="being in subjects of Turkish origin. The genotypic diversity across" exact="MENA" post="countries as well as the small sample size of"/>
  <result pre="be conducted in patient populations originating from countries of the" exact="MENA" post="region that have not yet been assessed. Future research"/>
  <result pre="with eosinophilia and systemic symptoms) in populations originating within the" exact="MENA" post="region. The presence of this allele has been associated"/>
  <result pre="variants significantly decrease phenytoin metabolism in patients originating from the" exact="MENA" post="region. The impacts of CYP2C19 and MDR1 C3435T polymorphisms"/>
  <result pre="G2677A/T and C3435T) and their genotype/haplotype combinations with the familial" exact="Mediterranean" post="feverXenobiotica.2014441093394010.3109/00498254.2014.91507124773260 116.DogruerDTugEBesCSoyMLack of an effect of CYP3A4 and MDR1"/>
  <result pre="gene polymorphisms on colchicine pharmacogenetics in the treatment of familial" exact="Mediterranean" post="feverGenet Mol Res.20131233521352810.4238/2013.January.24.223408444 117.AkbasSHBilgenTKeserITuncerMYucetinLTosunOet al.The effect of MDR1 (ABCB1)"/>
 </snippets>
</snippetsTree>
